NTRK1 and cancer: Recent studies have reported that axitinib serves as a multi-receptor tyrosine kinase inhibitor to treat multiple cancers, and axitinib inhibits the VEGF receptor, platelet-derived growth factor receptor, and epidermal growth factor receptor (Ongkeko et al., 2005; Bran et al., 2009; Lawrence et al., 2015).